2006
DOI: 10.1016/j.ajo.2006.08.011
|View full text |Cite
|
Sign up to set email alerts
|

American Heart Association; American Stroke Association Stroke Council. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: co-sponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

13
406
0
26

Year Published

2007
2007
2016
2016

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 340 publications
(445 citation statements)
references
References 0 publications
13
406
0
26
Order By: Relevance
“…In fact stroke's incidence increases with age in both genders, with an incidence of 38% in adults over 75 years old. [2][3][4] However, despite stroke's high prevalence in the elderly, intravenous alteplase (intravenous recombinant tissue plasminogen activator [IV-rtPA]), the only approved treatment for pharmacological revascularization in acute ischemic stroke, is licensed only in Europe for use in patients younger than 80 years old. 5 This seems to be related with frequent under-representation or exclusion of patients over the age of 80 years from clinical trials leading to uncertainty about the risk-benefit profile in these patients.…”
Section: Introductionmentioning
confidence: 99%
“…In fact stroke's incidence increases with age in both genders, with an incidence of 38% in adults over 75 years old. [2][3][4] However, despite stroke's high prevalence in the elderly, intravenous alteplase (intravenous recombinant tissue plasminogen activator [IV-rtPA]), the only approved treatment for pharmacological revascularization in acute ischemic stroke, is licensed only in Europe for use in patients younger than 80 years old. 5 This seems to be related with frequent under-representation or exclusion of patients over the age of 80 years from clinical trials leading to uncertainty about the risk-benefit profile in these patients.…”
Section: Introductionmentioning
confidence: 99%
“…For this purpose, we conducted a prospective investigation on asymptomatic subjects who received indication for the best medical therapy for each vascular risk condition. 14 …”
Section: Introductionmentioning
confidence: 99%
“…Carotid artery stenosis is a treatable risk factor for ischaemic stroke [1][2][3][4]. Current guidelines recommend endarterectomy or stent-protected percutaneous transluminal angioplasty as treatments for symptomatic severe carotid stenosis with 70-99% reduction in luminal diameter, as defined by the North American Symptomatic Carotid Endarterectomy Trial (NASCET) [1].…”
Section: Discussionmentioning
confidence: 99%
“…Symptomatic moderate degree carotid stenoses in the 50-69% range may equally require treatment [1]. In addition, in selected patients with asymptomatic 60-99% carotid stenosis, endarterectomy may also be considered as a primary preventative measure according to current guidelines [2]. Quantitative assessment of carotid stenosis is thus an essential prerequisite for therapeutic decision-making in individual cases [18].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation